Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

N4 PHARMA PLC Share Issue/Capital Change 2017

Oct 2, 2017

7804_rns_2017-10-02_d743626c-186d-4762-8b6f-8c917783b467.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

October 2, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), in conformity with DTR 5.6 of the FCA's Disclosure and Transparency Rules, notifies the market that as at 30 September 2017, the issued ordinary share capital of the Company consisted of 105,017,401 ordinary shares with voting rights attached (one vote per ordinary share). There are no ordinary shares held in treasury. 

The above total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Verona Pharma plc

Tel: +44 (0)20 3283 4200

Jan-Anders Karlsson, Chief Executive Officer

[email protected]

Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)

Stewart Wallace / Jonathan Senior / Ben Maddison

Tel: +44 (0) 20 7710 7600

[email protected]


*This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Verona Pharma plc via Globenewswire*